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Aims: Endothelin-1 (ET-1) has been shown to increase endothelial superoxide (O2−) production in experi-
mental animal models. It is unclear whether ET-1 increases O2− production in humans. We sought to elucidate
whether ET-1 increases O2− production in human vessels and to identify the mechanism behind this effect.
Main methods: Segments of internal mammary artery (IMA) and human saphenous vein (HSV) were har-
vested from 90 patients undergoing elective coronary artery bypass graft surgery. Paired vessel rings were
incubated in the presence and absence of ET-1 (10−10 M), the ETA receptor antagonist BQ123 alone, or in
combination with the ETB receptor antagonist BQ788 (dual BQ) and known inhibitors of sources of O2
− and
further analysed for O2− production using lucigenin-enhanced chemiluminescence and DHE ﬂuorescence.
−Key ﬁndings: ET-1 increased O2 production in both IMA (2.6±1.5 vs. 1.4±0.8 relative light units/s/mg tissue
(RLU); n=33; pb0.0001) and HSV (1.4±0.8 vs. 1.1±0.6 RLU; n=24; pb0.05). The increase in O2
− produc-
tion induced by ET-1 in IMA was inhibited by co-incubation with dual BQ (pb0.05; n=15) and BQ123
(pb0.05; n=17). Of known O2− inhibitors, only incubation with Tiron and diphenyleneiodonium resulted
in a signiﬁcant reduction in ET-mediated O2− production.
Signiﬁcance: ET-1 increases O2
− production especially in human arteries and less so in veins from patients with
coronary artery disease via a receptor-dependent pathway involving a ﬂavin dependent enzyme which is likely
to be NADPH oxidase. Production of O2−may be an important factor underlying the negative effects of ET-1 on
vascular function such as impairment of endothelium-dependent vasodilatation and pro-inﬂammatory effects.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
The development of atherosclerosis occurs in the presence of risk
factors such as diabetes, hypertension and hypercholesterolemia.
These vascular disease states present a disturbed internal balance be-
tween vasodilator and vasoconstrictor activity and an increase in the
production of reactive oxygen species (ROS) (Munzel et al., 2008).
ROS naturally exist in the vessel wall and act as intracellular signal-
ling molecules inﬂuencing cell growth (Buetler et al., 2004). When
ROS production exceeds the antioxidant defences, pathological effects
of ROS are seen, which may be the case following reduced bioavail-
ability of nitric oxide (NO) due to rapid chemical inactivation
(Ignarro et al., 1987). Reduced bioavailability of NO is associated
with increased levels of the vasoconstrictive peptide endothelin-1
(ET-1) that contribute to endothelial dysfunction in atherosclerosis
(Böhm et al., 2002b; Lerman et al., 1991, 1995). ET-1 is predominant-
ly produced by vascular endothelial cells and exerts its effects, Karolinska University Hospi-
ax: +46 8 311101.
to).
-NC-ND license.through binding to two G-protein coupled membrane receptors: ETA
and ETB. A possible link between ET-1 and ROS production has been
suggested. ET-1 stimulates ROS production in human endothelial
and vascular smooth muscle cell cultures (VSMC) (Dong et al.,
2005; Duerrschmidt et al., 2000), as well as in different rat (Li et al.,
2003b; Loomis et al., 2005; Lopez-Sepulveda et al., 2010) and
mouse models (Li et al., 2003a). Both ETA (Li et al., 2003b) and ETB
(Dong et al., 2005; Duerrschmidt et al., 2000) receptors have been
suggested to contribute to superoxide (O2−) production from different
sources. However, there is limited understanding regarding the effect
of ET-1 on ROS production in human vessels. We have previously
shown that ET-1 infused in the forearm of patients with coronary ar-
tery disease (Böhm et al., 2002a) and healthy individuals (Böhm et al.,
2007) causes endothelial dysfunction. This impairment could in
healthy individuals be successfully inhibited by the antioxidant vita-
min C suggesting a possible involvement of ET-induced O2− produc-
tion. However, no measurement of ROS production was performed.
Thus, the effect of ET-1 on ROS production in intact human blood ves-
sels remains to be investigated. Therefore, the aim of the present
study was to investigate; (1) whether ET-1 increases O2− production
in human vessels, (2) if there exist differences in ET-induced O2−
724 R. Cerrato et al. / Life Sciences 91 (2012) 723–728production between human arteries and veins, (3) which ET receptor
that is involved in ET-induced O2− production, and (4) which source
of O2− that is predominantly involved in ET-induced O2− production.
Material and methods
Study subjects
We recruited 90 patients with CAD undergoing coronary artery
bypass grafting (CABG) at the John Radcliffe Hospital, Oxford, UK.
Inclusion criteria were coronary artery disease in need of elective
or subacute CABG and exclusion criteria were emergency CABG
and unwillingness to participate. Each patient gave oral and written
informed consent. The study was performed in accordance with the
Declaration of Helsinki. The study was approved by the local Research
Ethics Committee. Basal characteristics of the patients are presented in
Table 1.
Tissue samples
Samples of internal mammary artery (IMA, n=73) and saphenous
vein (HSV, n=24) were obtained at the time of CABG. The vessel seg-
ments were dissected free from surrounding tissue, rinsed from blood
and then quickly transported from surgery in ice-cold oxygenated
Krebs-Henseleit buffer to the laboratory.
Determination of vascular superoxide production
Vascular O2− production was measured in paired segments of IMA
and HSV with the use of lucigenin-enhanced chemiluminescence
(Guzik and Channon, 2005; Guzik et al., 2002). The protocol has
been validated and at the low dose of 5 μM lucigenin no redox cycling
has been detected (Dikalov et al., 2007; Guzik and Channon, 2005).
The segments were divided into 4–6 rings, each approximately
3 mm thick, depending on size, weight ranging from 6 to 20 mg/
ring. The vessels were opened longitudinally to expose the endotheli-
al surface and equilibrated in oxygenated (95% O2/5% CO2) Krebs-
HEPES buffer (pH 7.4) at 37 °C with and without ET-1 (10−10 M)
for 45 min. The incubation time was chosen based on our previous
studies showing marked reduction in endothelium-dependentTable 1
Individual characteristics of patients.
No of patients 90
Men/women 78/12
Age (y, mean±SD) 68±8
Risk factors, n (%)
Hypertension 63 (70)
Hypercholesterolemia 66 (73)
Smokers/exsmokers 14/46
Diabetes mellitus 26 (28)
Type II 23 (89)
Family history 43 (48)
Body mass index, kg/m2 28±4
Elective/acute surgery
Angiographic extent of CAD, n (%) 82/8
1-vessel disease 2 (2)
2-vessel disease 19 (21)
3-vessel disease 69 (77)
Medication, n (%)
Statins 79 (88)
Angiotensin-converting enzyme inhibitors 37 (41)
Angiotensin receptor blockers 16 (18)
Calcium channel blockers 21 (23)
Betablockers 63 (70)
Nitrates 35 (39)
Aspirin 71 (79)
Clopidogrel 20 (22)
Diuretics 7 (8)
Values are expressed as mean±SD.vasodilatation in the human forearm following 30–60 min infusion
of ET-1 (Böhm et al., 2002a, 2007; Lerman et al., 1995). The vessel
segment was then quickly transferred to a luminometer containing
low-concentration lucigenin (5 μmol/L) in order to measure O2− pro-
duction. In subgroups, a dose-ranging study for ET-1 (10−11 to
10−8 M) was performed. Furthermore, additional rings were ana-
lysed after 20 min preincubation with either the ETA receptor antago-
nist BQ123 (10−6 M) alone, or in combination with the ETB receptor
antagonist BQ788 (10−6 M; dual BQ), the inhibitor of ﬂavin depen-
dent enzymes diphenyleneiodonium (DPI, 5×10−5 M), the inhibitor
of nitric oxide synthase L-nitro arginine methyl ester (L-NAME;
10−4 M), the inhibitor of xanthine oxidase oxypurinol (10−5 M),
the inhibitor of mitochondrial ROS rotenone (10−4 M), the superox-
ide scavenger Tiron (10−6 M) and the inhibitor of the assembly of
NADPH oxidase apocynin (5×10−4 M). Following this preincubation,
ET-1 was added for 45 min in each subgroup.
Oxidative ﬂuorescent microphotography
In situ O2− production was determined in vessel cryosections with
the oxidative ﬂuorescent dye dihydroethidium (DHE) as previously
described (Bendall et al., 2007). Paired vessel segments were incubat-
ed in the presence or absence of ET-1 (10−10 M) in Krebs-HEPES buff-
er for 45 min at 37 °C and then snap frozen in Tissue Tek OCT.
Cryosections (30 μm) were equilibrated in the presence or absence
of ET-1 for 30 min at 37 °C and then exposed to DHE (2 μmol/L) for
5 min. Fluorescence images of the endothelium (40x, Zeiss LSM 510
META laser scanning confocal microscope) were obtained from each
vessel quadrant. Segments of vessel rings (with and without ET-1,
n=3) were analysed in parallel with identical imaging parameters.
DHE ﬂuorescence was quantiﬁed by automated image analysis with
Image-Pro Plus software (Media Cybernetics, Bethesda, MD, USA).
Substances
ET-1, BQ123 and BQ788 (NeoMPS, Strasbourg, France) were all
dissolved in Millipore ﬁltered water and stored frozen at −20 °C.
Apocynin, oxypurinol, rotenone, Tiron, DPI and L-NAME (Sigma Al-
drich, UK), were dissolved according to the manufacturer's instruc-
tions and stored frozen at −20 °C. DHE (Invitrogen, UK), was
dissolved in DMSO according to manufacturer's instructions.
Statistical analysis
Data are expressed as means±SD if not stated otherwise. All
variables were tested for normal distribution with the use of
D'Agostino–Pearson normality test. Statistical differences were cal-
culated by using Students paired t-test for between group com-
parisons. All statistical analyses were performed using Graph Pad
4.0 Prism Plus software.
Results
ET-mediated O2
− production
A dose-ranging study revealed a marked increase in O2− produc-
tion by ET-1 in IMA already from 10−10 M (Fig. 1a). This dose was
therefore used in the subsequent studies. ET-1 induced a signiﬁcant
increase in O2− production in both IMA (Fig. 1b) and HSV (Fig. 1c).
ET-1 had a signiﬁcantly more pronounced effect on O2− production
in IMA than in HSV (Fig. 1d).
In addition to O2− production measured by chemiluminescence,
DHE staining of cryosections of IMA was performed in order to histo-
logically visualize the possible intracellular source of ET-mediated O2−
production. Fig. 2 shows DHE-stained cryosections of control and ET-
treated IMA. The integrity of the vessel was kept with intact basal
Fig. 1. (a): dose ranging study of ET-1 showing effect of 45 min ET-1 (0.01–10 nM) incubation on O2− production as determined by lucigenin-enhanced chemiluminescence in
paired internal mammary arteries, n=8. (b): effect of ET-1 (0.1 nM) on O2− production in paired internal mammary arteries (n=33) and (c): in paired saphenous veins
(n=24). (d) Delta increase of vascular O2− production in internal mammary arteries and saphenous veins. Data are presented as means and SD; *pb0.05, **pb0.001, ***pb0.0001.
Fig. 2. Effect of 45 min ET-1 (0.1 nM) incubation on O2− production in a representative
example of paired internal mammary arteries (n=3) as determined by DHE ﬂuores-
cence (red staining indicated with white arrows, green staining represents basal auto-
ﬂuorescence), 40× magniﬁcation.
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ing from spindle shaped cells in ET-treated cryosections suggesting
that a predominant fraction of ET-mediated O2− production originates
from vascular smooth muscle cells.
ET-1 mediates O2
− production via a receptor-dependent mechanism
Since the O2− production stimulated by ET-1 was signiﬁcantly
greater in IMA than in HSV, IMA was chosen for further mechanistic
studies of ET-induced O2− production. To investigate whether ET-1
mediate O2− production via a receptor-dependent mechanism and to
determine which receptor is most important for mediating O2− pro-
duction, paired IMA rings were incubated in the presence of ET-1
and the selective ETA receptor antagonist BQ123 or dual ETA/ETB
blockade. The increase in O2− production induced by ET-1 in IMA
was markedly inhibited by pre-incubation with BQ123 (pb0.05;
Fig. 3) as well as by dual BQ (pb0.05; Fig. 3).
Sources of ET-mediated O2
− in human vessels
In order to investigate through which enzymatic source ET-1 me-
diates its effects on O2− production in IMA, we incubated paired IMA
segments with inhibitors of known O2− sources such as xanthine oxi-
dases (oxypurinol), mitochondrial ROS (rotenone), eNOS uncoupling
(L-NAME), and NADPH oxidases (DPI and apocynin). To conﬁrm the
results we also incubated with the superoxide scavenger Tiron. Incu-
bation with Tiron and DPI (Fig. 4a) could signiﬁcantly inhibit ET-
induced O2− production. Incubation with apocynin, oxypurinol, rote-
none and L-NAME had no effect on O2− levels stimulated by ET-1
(Fig. 4b).
Discussion
The main ﬁndings are that (1) ET-1 induces a signiﬁcant increase
in O2− in human arteries and veins used for CABG, (2) ET-induced
O2− production is more pronounced in IMA than in HSV, (3) ET-
mediated O2− production occurs via a receptor-dependent mecha-
nism, predominantly via the ETA receptor and (4) ET-induced O2− pro-
duction is dependent on NADPH oxidase.
Fig. 3. Effect of 45 min ET-1 (0.1 nM) incubation on O2− production in paired internal
mammary arteries with and without 20 min pre-incubation of BQ123 (10 μM) alone
(n=15) and in combination with BQ788 (10 μM; n=17). Data are presented as
means and SD; *pb0.05.
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duction and is involved in initiating and maintaining endothelial dys-
function (Schiffrin, 2001). Furthermore, ET receptor blockade has
been shown to improve endothelial function in human coronary ar-
teries (Verma et al., 2001). However, there are no studies that have
determined whether ET-1 stimulates O2− production in human arter-
ies and the pathophysiological link to endothelial dysfunction re-
mains unknown. In this study we therefore ﬁrst sought to
investigate whether exogenous ET-1 increases ROS production in
human vessels from patients with CAD. ET-1 produced a signiﬁcantFig. 4. Effect of 45 min ET-1 (0.1 nM) incubation on O2− production in paired internal
mammary arteries with and without 20 min pre-incubation with (a) Tiron: n=6 and
DPI: n=9, (b) rotenone: n=7, L-NAME: n=14, oxypurinol: n=7, apocynin: n=7.
Data are presented as means and SD; **pb0.001.increase in O2− production with a clear effect at 10−10 M. This con-
centration of ET-1 is considerably lower than those in previously pre-
sented studies on ET-induced O2− production (Duerrschmidt et al.,
2000; Ergul et al., 2005; Loomis et al., 2005; Touyz et al., 2004)
which have used concentrations ranging from 10−6 to 10−9 M. Sev-
eral studies have shown that patients with CAD have increased levels
of circulating ET-1 (Hedman et al., 2007; Sabatine et al., 2012; Yip et
al., 2005). These levels are usually in picomolar range and its biolog-
ical effect is unclear since secretion of ET-1 predominantly occurs
abluminally. ET-1 immunoreactivity expressed in histological stain-
ing has been studied in vascular tissue from patients with CAD show-
ing an increased percentage of positive staining particularly in
mammary arteries (Sutherland et al., 2006) but to our knowledge
no attempts have been made to measure the actual concentrations
of intracellular ET-1 in these tissues and also study functional out-
comes. We conclude that mammary arteries are not ET-1 naive and
at low concentrations of exogenous ET-1 clear effects on ROS genera-
tion can be seen. Future studies would need to further investigate the
correlation of intracellular levels of ET-1 and ROS generation. In this
study we observed differences in ET-1 induced O2− production be-
tween IMA and HSV. This may be due to difference in structure,
with HSV having more adventitia and less VSMC than IMA, but also
differences in vascular contractility to ET-1, ET receptor expression
and level of endothelin converting enzyme activity between the two
vessel types (Heigl et al., 2002). In contrast we could not observe a
difference in basal levels of O2− production between IMA and HSV
i.e. prior to ET-1 stimulation suggesting that intrinsic differences be-
came apparent on outcome only when ET-1 was added to the vessels.
In order to investigate whether ET-1 mediates O2− production via a
receptor-dependent pathway we exposed paired segments of IMA to
ET-1 in combination with its receptor antagonists BQ123 (ETA) alone
or in combination with BQ788 (ETB). In vitro studies show that both
receptors can contribute to O2− production (Dong et al., 2005; Li et
al., 2003b). In our study we demonstrate a clear reduction of ET-
induced O2− production by selective ETA receptor blockade and no ad-
ditional effect of dual ETA/ETB receptor blockade. These observations
suggest that ETA is the predominant receptor mediating arterial ROS
production. Activation of ETB receptors expressed on VSMC results
in vasoconstriction, cell proliferation and superoxide production
(Böhm and Pernow, 2007). In contrast, activation of ETB receptors
on endothelial cells leads to release of NO which may reduce O2− bio-
availability (d'Uscio et al., 2000). According to our results, the net ef-
fect of blocking both the endothelial and the VSMC ETB receptor does
not result in additional inhibition of ET-induced O2− production. In ac-
cordance with these ﬁndings we also noted an increase in DHE signal
coming from the media which indicates that the ET-induced O2− pro-
duction predominantly originates from vascular smooth muscle cells
which have an abundance of ETA receptors (Schiffrin, 2001). Interest-
ingly, O2− generation may increase atherosclerosis by activating VSMC
mitogenic signalling pathways (Vendrov et al., 2007). This ﬁnding to-
gether with our results indicates that blocking ET-induced O2− pro-
duction may be one mechanism behind the anti-atherosclerotic
effect of ET receptor blockade (Barton et al., 1998).
It is not clear which enzymatic source of O2− that causes ET-
mediated O2− production and therefore we sought to study this fur-
ther. Since inhibition of basal O2− has been studied in detail (Guzik
et al., 2006) we sought to focus on the inhibition of ET-induced O2−
production. In this study ET-induced O2− production is signiﬁcantly
inhibited only by Tiron — a superoxide scavenger — and DPI — an in-
hibitor of ﬂavin dependent enzymes such as NADPH oxidase, xan-
thine oxidases and NOS. Speciﬁc inhibition of NOS, xanthine
oxidases and mitochondrial enzymes did not inhibit ET-induced O2−
indicating that it is unlikely that these enzyme systems contribute
to ET-induced O2− production. Accordingly we conclude that NADPH
oxidase is likely to have contributed substantially to the O2− produc-
tion that was observed following incubation with ET-1. This is in
727R. Cerrato et al. / Life Sciences 91 (2012) 723–728accordance with a previous report which demonstrated that ET-1 in-
creases vascular O2− generation via NADPH oxidase in a model of low-
renin hypertension (Li et al., 2003b). It is possible that this increase in
O2− production is mainly due to a membrane-bound NADPH oxidase
activity as suggested in a study on pig coronary arteries (Brandes et
al., 1997). However, Ergul et al., 2005 could not detect any increase
in NADPH oxidase-mediated O2− production following ET-1 incuba-
tion in HSV. This difference may be due to the fact that frozen and ho-
mogenized HSV instead of fresh IMA were used. Surprisingly
apocynin did not inhibit O2− production in our study. Apocynin in-
hibits the release of O2− by NADPH oxidase by blocking p47 phox
and its translocation to the membrane and therefore blocks the as-
sembly of NADPH oxidase (Stolk et al., 1994). Apocynin is also a
prodrug which requires metabolic activation (oxidation) by myelo-
peroxidases (MPO) in order to form active dimers (Wind et al.,
2010) and there are conﬂicting data on whether endothelial cells
and vascular smooth muscle cells can form these dimers and there-
fore also activate apocynin (Heumuller et al., 2008; Touyz, 2008).
Since apocynin can act as a radical scavenger but also stimulate ROS
generation as discussed by Heumuller and Touyz it seems imperative
that any further study of whether NADPH oxidase is involved in ET-1
ROS generation in humans should include models that are not depen-
dent on the inhibitor per se. With the current knowledge at hand and
the vascular model chosen in this study we conclude that the absence
of inhibition of O2− by apocynin in this vascular model does not nec-
essarily exclude a role for NADPH oxidase in ET-1 mediated O2−.
In the human vasculature four isoforms of NADPH oxidase have
been identiﬁed; nox 1 in endothelial cells (EC), nox 2 and 5 in EC
and VSMC and nox 4 in all cell types. There is a signiﬁcant increase
in expression and activity of these nox subunits in the setting of vas-
cular disease states such as diabetes, hypercholesterolemia and hy-
pertension (Brandes et al., 2010; Leto et al., 2009; Montezano et al.,
2011). NADPH oxidase-derived ROS results in negative modulation
of vascular tone and stimulation of pro-inﬂammatory responses
(Paravicini and Touyz, 2008). In our study we observed a signiﬁcant
increase in O2− production already after 45 min of ET-1 exposure sug-
gesting a rapid stimulation of NADPH oxidase activity. To our knowl-
edge there are no studies performed on human vessels describing the
source of ET-mediated O2− production and a possible intracellular
pathway in the same study. A previous report shows that ET-1 in-
creases expression and activity of p47 phox in rat aortic rings via
the ETA receptor which would suggest that ET-1 is critically involved
in the activation of NADPH oxidase (Romero et al., 2010). The signal-
ling pathway suggested was sequential activation of protein kinase C
(PKC), c-Src and ERK 1/2. Whether the ERK–MAPK pathway is in-
volved in ET-induced O2− production is still unclear. Romero et al.
(2010) could not see any acute (i.e. within 60 min) effect of ET-1 on
O2− production but the effect described occurred after 2 h. It is there-
fore possible that in vessels from CAD patients, which may have upre-
gulated pro-inﬂammatory activity, a different pattern of stimulation
and activation of NADPH oxidase occurs.
The following limitations were identiﬁed; ﬁrst the study cohort
should ideally include healthy controls not only because of differ-
ence in vascular pathophysiology but also due to ongoing medica-
tion such as statins, ACE inhibitors and beta blockers which
will have speciﬁc effects on O2− generation among patients. The
ﬁnding that ET receptor blockade reduced O2− production in vessels
from patients included in the present study may be of clinical im-
portance since it demonstrates pathophysiological effects of ET-1
on top of standard treatment in CAD. Second, the ET-mediated O2−
production was measured in vessels ex-vivo and the present ﬁnd-
ings cannot be extrapolated to in vivo conditions. However, it is of
interest that ET-1 induces endothelial dysfunction also in vivo via
a mechanism that is related to oxidative processes (Böhm et al.,
2007). Third, the small amount of tissue limits the possibility for
multiple observations in each patient. However, each observationwas from paired samples from the same patient and the study co-
hort was relatively large.
Conclusions
We conclude that ET-1 increases O2− production especially in
human arteries and less so in veins from patients with CAD via a
receptor-dependent pathway involving NADPH oxidase. Production
of O2−may contribute to negative effects of ET-1 on vascular function
such as impairment of endothelium-dependent vasodilatation and
pro-inﬂammatory effects. Beneﬁcial effects of ET receptor blockade
in patients with CAD may be related to reduced production of O2−.
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